Table 1.
Characteristics of groups studied.
| Patients | Controls | |
|---|---|---|
| n | 87 | 48 |
| Median age (range, years) | 41·5 (18–75) | 37 (18–68) |
| Female/male (%) | 55/45 | 56/44 |
| Median FEV1 (range, %) | 71 (36–113) | n.a. |
| Median ICS (range, µg per day)a | 1600 (800–4800)* | 0 |
| Oral GCS (range, mg per day)b | 5 (0–25) | 0 |
| Aspirin intolerance (%) | 13·8 | 0 |
| Chronic rhinosinusitis (%) | 33 | 0 |
| Median eosinophilic count (range, cell/mm3) | 200 (0–1326) | n.a. |
a
Calculated as budesonide equivalent
b
calculated as prednisone equivalent.
*
Some patients received inhaled corticosteroids (ICS) in nebulization. FEV1: forced expiratory volume in 1 second; GCS: glucocorticosteroids.